What data is specifically used to identify drug diversion issues?

Chargeback data is essential in identifying drug diversion issues because it provides detailed insights into the transactions that occur between healthcare providers and suppliers. This data reveals discrepancies between what a provider orders and what is actually billed or credited back. By analyzing chargeback transactions, organizations can detect patterns or anomalies that may indicate potential diversion of drugs, such as unexpected returns or unusually high levels of products returned that do not align with average usage patterns.

Utilization data, while helpful in understanding overall drug use within a facility, does not specifically pinpoint where diversion might be occurring. Similarly, inventory data can provide insight into stock levels but does not track the financial aspects or any irregularities in supply movements. Reimbursement data similarly focuses on the financial transactions and correct payments but may not reflect the specifics of inventory management or diversion concerns as effectively as chargeback data does.